Clinical Trial

A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase Ⅲ comparative study to evaluate the efficacy and safety of QL2108 to Dupixent® in adult subjects with moderate-to-severe atopic dermatitis. A total of 520 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2108 injection or Dupixent®
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-13.
Trial Details
NCT Number NCT06884891
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Atopic Dermatitis
Enrollment 520 participants
Start Date 2025-04
Primary Completion 2027-05 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-03-21